fezolinetant: Clinical Trials

9 trials of fezolinetant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 recruiting, 1 terminated. 9 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 4, Recruiting 4, Terminated 1
Phase 31Recruiting 1

Follow fezolinetant: new trials by email Literature Review of fezolinetant trials Research Report on fezolinetant

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
Fezolinetant, Placebo - Vasomotor Symptoms, Prostate Cancer
Phase 2RecruitingChinese University of Hong Kong542026-10-052026-10-07
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Metformin, semaglutide, Anti-hypertensives - Menopause, Menopause Hot Flashes
Phase 2 / Phase 3RecruitingUniversity of Colorado, Denver2002026-03-012026-11-04
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
Fezolinetant - Prostate CA, Androgen Deprivation Therapy
Phase 2RecruitingUniversity of Vermont322025-12-182026-02-05
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Fezolinetant, Placebo - Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Phase 2RecruitingYale University922025-12-052026-11-03
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
Fezolinetant, Placebo - Hot Flashes
Phase 2CompletedAstellas Pharma Global Development, Inc.1502025-03-102026-03-19
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
Biospecimen Collection, Fezolinetant, Placebo Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 2TerminatedUniversity of Michigan Rogel Cancer Center92024-10-312026-05-06
A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
Fezolinetant, Placebo - Hot Flashes
Phase 2CompletedAstellas Pharma Inc1472021-11-172024-10-26
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Fezolinetant, Placebo - Menopause, Hot Flashes
Phase 2CompletedAstellas Pharma Global Development, Inc.3562017-07-192024-11-26
Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
Fezolinetant, Placebo - Hot Flashes
Phase 2CompletedOgeda S.A.872015-09-212024-11-27

Conditions studied

Hot Flashes (5)  ·  Prostatic Neoplasms (2)  ·  Carcinoma, Intraductal, Noninfiltrating (1)

Sponsors

Astellas Pharma Global Development, Inc. (2)  ·  Astellas Pharma Inc (1)  ·  Chinese University of Hong Kong (1)  ·  Ogeda S.A. (1)  ·  University of Colorado, Denver (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  University of Vermont (1)  ·  Yale University (1)

Countries

United States (5)  ·  Belgium (1)  ·  China (1)  ·  Hong Kong (1)  ·  Japan (1)

Top investigators

Chi Fai NG, MD (1)  ·  Maryam Lustberg, MD (1)  ·  Nanette Santoro, MD (1)  ·  Norah L Henry (1)

Results publications

PMID 31415087, PMID 32102086

NIH funding

2015 (1)